Completed PHASE2 INTERVENTIONAL 1-arm NCT06820320

Oral Iohexol in the Management of Chylous Ascites After After Retroperitoneal or Extended Lymphadenectomy

Oral Iohexol in the Management of Chylous Ascites After Retroperitoneal or Extended Lymphadenectomy for Abdominal or Pelvic Malignant Tumor: An Innovative and Convenient Treatment

Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Conditions Abdominal Neoplasm Chylous Ascites Extended Lymphadenectomy Pelvic Neoplasms Retroperitoneal Lymph Node Metastasis Retroperitoneal Lymphadenectomy

Interventions Lymphangiography and Embolization oral iohexol

Updated 2 times since 2025 Last updated: Mar 4, 2026 Started: Feb 15, 2025 Primary completion: Dec 31, 2025 Completion: Dec 31, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Abdominal Neoplasm and Chylous Ascites and is currently completed. Cancer Institute and Hospital, Chinese Academy of Medical Sciences leads this study, which shows 2 recorded versions since 2025 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

2 versions recorded

Mar 2026 — Present [monthly]

Completed PHASE2

Status: Not Yet Recruiting → Completed
Mar 2025 — Mar 2026 [monthly]

Not Yet Recruiting PHASE2

First recorded

Feb 2025

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Data source: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China